Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXACT: Zanzalintinib +/- Nivolumab in Clear Cell RCC
NCT06863311Phase 2Recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in clear cell renal cell carcinoma (ccRCC). Started Mar 2026; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06863311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863311.